© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
Study: Here’s Some Evidence That Switching Among Generic Levothyroxine Products Is OK
March 01, 2022
Guidelines tell prescribers and patients to avoid switching among levothyroxine products from different manufacturers. But Mayo Clinc-led research finds little difference between switchers and nonswitchers.
Cardinal Health Predicts 2022 to be Turning Point for Biosimilars in the U.S.
February 21, 2022
New report includes research findings on insulin biosimilars use among retail pharmacists and physicians.
Vizient Drug Report: Remdesivir Knocks Humira Off As Top Drug Spend
January 28, 2022
Humira may sink even further in the drug spend rankings next year when six biosimilars are expected to hit the market.
Top 4 Biosimilar Developments of 2021
December 10, 2021
2021 was an outstanding year for biosimilar medications, as they increased market share and adoption by healthcare providers and the first biosimilar and interchangeable insulin was approved by the FDA. Take a look at Managed Healthcare Executive's top four biosimilar developments of 2021.
Sandoz Executive Talks About Cost Savings From Biosimilar Insulins — and the Challenges
December 09, 2021
A temporary add-on payment in the Part B program should be considered as a way to increase biosimilar uptake, says Sandoz’s Afton Wagner.
What’s Next for the Biosimilars Market in the U.S.?
November 22, 2021
Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.
Priming the Pump for Interchangeable Biosimilars By Preferencing Semglee
November 04, 2021
By giving Semglee, the interchangeable biosimilar for Lantus, a preferred spot on its formulary, the Prime Therapeutics says it is setting the stage for other interchangeables coming down the pike, including the one for Humira.
Biosimilars Could Wind Up Saving $7.8 Billion in 2021, Says California Think Tank
November 04, 2021
Biosimilars can save states billions of dollars annually, according to a new report from a libertarian think tank in California.
Biosimilar Growth Impressive But New Policies Needed, AAM Exec Says
October 08, 2021
Three pieces of legislation that would provide incentives to prescribers and put generics and biosimilars in favorable formulary tiers would speed further prescribing and use of biosimilars, Christine Simmon told Managed Healthcare Executive.®
AAO Spokesperson: FDA Approval of Byooviz, First Biosimilar to Lucentis, Is “Significant"
October 07, 2021
Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.